A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

[1]  J. Bertherat,et al.  Clinical Biology of the Pituitary Adenoma , 2022, Endocrine reviews.

[2]  S. Melmed,et al.  Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States , 2022, Pituitary.

[3]  L. Kasuki,et al.  The future of somatostatin receptor ligands in acromegaly. , 2021, The Journal of clinical endocrinology and metabolism.

[4]  M. Fleseriu,et al.  More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY , 2021, European journal of endocrinology.

[5]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[6]  M. Fleseriu,et al.  Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era , 2021, Endocrine.

[7]  L. Fenoglio,et al.  Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment , 2020, Pituitary.

[8]  S. Samson,et al.  A Pituitary Society update to acromegaly management guidelines , 2020, Pituitary.

[9]  P. Chanson,et al.  Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study , 2020, Endocrine.

[10]  P. Chanson,et al.  Multidisciplinary management of acromegaly: A consensus , 2020, Reviews in Endocrine and Metabolic Disorders.

[11]  M. Marazuela,et al.  Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly , 2020, Endocrine.

[12]  S. Melmed,et al.  Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. , 2020, The Journal of clinical endocrinology and metabolism.

[13]  H. Marcus,et al.  Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective , 2020, Pituitary.

[14]  F. Casanueva,et al.  A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. , 2020, The Journal of clinical endocrinology and metabolism.

[15]  R. Vettor,et al.  Pegvisomant: daily versus non daily administration a single centre real life study , 2019, Endocrine Abstracts.

[16]  C. Alvarez-Escola,et al.  ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. , 2019, Endocrinologia, diabetes y nutricion.

[17]  R. Oprean,et al.  An overview of the common methods used to measure treatment adherence , 2019, Medicine and pharmacy reports.

[18]  F. Cordido,et al.  Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study , 2019, Pituitary.

[19]  M. Fleseriu,et al.  Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. , 2018, Endocrine reviews.

[20]  P. Chanson,et al.  Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study , 2018, Endocrine.

[21]  P. Chanson,et al.  A Consensus Statement on acromegaly therapeutic outcomes , 2018, Nature Reviews Endocrinology.

[22]  A. J. van der Lely,et al.  Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study) , 2017, The Journal of clinical endocrinology and metabolism.

[23]  R. Robbins,et al.  Cardiovascular Disease in Acromegaly. , 2017, Methodist DeBakey cardiovascular journal.

[24]  T. Brue,et al.  The risks of overlooking the diagnosis of secreting pituitary adenomas , 2016, Orphanet Journal of Rare Diseases.

[25]  J. Jørgensen,et al.  What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy? , 2016, European journal of endocrinology.

[26]  J. Jørgensen,et al.  Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. , 2015, European journal of endocrinology.

[27]  A. Colao,et al.  Adverse events associated with somatostatin analogs in acromegaly , 2015, Expert opinion on drug safety.

[28]  M. Gadelha,et al.  Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study , 2015, European journal of endocrinology.

[29]  M. Ortiz.  Benefits of less frequent injections in advanced prostate cancer. , 2015, Australian family physician.

[30]  M. Wilcox,et al.  The Control of Methicillin-Resistant Staphylococcus aureus Blood Stream Infections in England , 2015, Open forum infectious diseases.

[31]  A. Spanevello,et al.  Estimation of Minimal Clinically Important Difference in EQ-5D Visual Analog Scale Score After Pulmonary Rehabilitation in Subjects With COPD , 2015, Respiratory Care.

[32]  G. Vargas,et al.  Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center , 2015, Pituitary.

[33]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[34]  M. Sampedro-Núñez,et al.  Cabergoline treatment in acromegaly: pros , 2014, Endocrine.

[35]  L. Nachtigall,et al.  Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment , 2013, International journal of general medicine.

[36]  K. Gariani,et al.  Implications of Somatostatin Analogues in the Treatment of Acromegaly. , 2013, European endocrinology.

[37]  D. Revicki,et al.  Pharmacoeconomic Evaluation in the Real World , 1999, PharmacoEconomics.

[38]  H. Orskov,et al.  Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. , 2011, The Journal of clinical endocrinology and metabolism.

[39]  S. Melmed,et al.  Clinical, quality of life, and economic value of acromegaly disease control , 2011, Pituitary.

[40]  P. Caron,et al.  Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. , 2011, European journal of endocrinology.

[41]  K. Badenhoop,et al.  Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[42]  S. Manjila,et al.  Pharmacological management of acromegaly: a current perspective. , 2010, Neurosurgical focus.

[43]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[44]  E. Tacconelli.  Systematic reviews: CRD's guidance for undertaking reviews in health care , 2010 .

[45]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[46]  A. Colao,et al.  Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegaly , 2009, Clinical endocrinology.

[47]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[48]  A. J. van der Lely,et al.  Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. , 2009, European journal of endocrinology.

[49]  G. Arnaldi,et al.  Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly , 2009, Journal of endocrinological investigation.

[50]  W. Drake,et al.  Successful use of weekly pegvisomant administration in patients with acromegaly. , 2008, European journal of endocrinology.

[51]  X. Badia,et al.  Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. , 2009, The Journal of clinical endocrinology and metabolism.

[52]  R. Abs,et al.  Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. , 2007, European journal of endocrinology.

[53]  S. Grottoli,et al.  Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study , 2007, Clinical endocrinology.

[54]  I. Martínez-Delgado,et al.  [Usefulness of GH and IGF-1 to establish the dose and frequency of application of octreotide to treat acromegaly]. , 2007, Revista medica del Instituto Mexicano del Seguro Social.

[55]  A. J. van der Lely,et al.  Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.

[56]  R. Astorga,et al.  Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial , 2006, Clinical endocrinology.

[57]  J. Wass,et al.  Systematic dose‐extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly , 2004, Clinical endocrinology.

[58]  Robert C. Lee,et al.  STANDARD QUALITY ASSESSMENT CRITERIA FOR EVALUATING PRIMARY RESEARCH PAPERS FROM A VARIETY OF FIELDS , 2004 .

[59]  J. Romijn,et al.  Sandostatin LAR in acromegaly: a 6‐week injection interval suppresses GH secretion as effectively as a 4‐week interval , 2003, Clinical endocrinology.

[60]  D. Revicki,et al.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. , 1999, PharmacoEconomics.